BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To improve the efficacy of ASNase treatment, we used a CRISPR/Cas9-based screen to identify actionable signaling intermediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Miriam, van Ingen Schenau, Dorette S., Yu, Jiangyan, Jenni, Silvia, Dobay, Maria P., Hagelaar, Rico, Vervoort, Britt M. T., Tee, Trisha M., Hoff, Fieke W., Meijerink, Jules P., Kornblau, Steven M., Bornhauser, Beat, Bourquin, Jean-Pierre, Kuiper, Roland P., van der Meer, Laurens T., van Leeuwen, Frank N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832462/
https://www.ncbi.nlm.nih.gov/pubmed/34280258
http://dx.doi.org/10.1182/blood.2021011787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832462/
https://www.ncbi.nlm.nih.gov/pubmed/34280258
http://dx.doi.org/10.1182/blood.2021011787

Ejemplares similares